Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

March 3, 2021March 3, 2021

Ilixadencel-Sutent Combo Shows ‘Meaningful’ Survival in Advanced Kidney Cancer Patients

News

A combination of ilixadencel plus first-line treatment with Sutent (sunitinib) prolonged overall survival to a clinically meaningful extent in newly diagnosed patients with metastatic renal cell carcinoma (mRCC), a form of ... Read more

March 1, 2021March 1, 2021

Imfinzi No Longer Available in US for Advanced Bladder Cancer

News

After consulting with the U.S. Food and Drug Administration (FDA), AstraZeneca has announced that Imfinzi (durvalumab) — which last year failed a confirmatory Phase 3 trial — will no longer ... Read more

February 19, 2021February 19, 2021

Opdivo Effective as Bladder Cancer Post-surgery Therapy, Data Show

News

Treatment with Opdivo (nivolumab) after surgery significantly delays disease recurrence or death in patients with muscle-invasive urothelial carcinoma, a form of bladder cancer that has spread to nearby muscles, according ... Read more

February 17, 2021February 17, 2021

FLX475 Shows Promising Safety, Anti-Tumor Activity; Trial Recruiting

News

FLX475, an investigational anti-cancer therapy by RAPT Therapeutics, is safe and shows promising anti-tumor clinical activity, both alone and in combination with Keytruda (pembrolizumab), in certain types of cancer. These ... Read more

February 8, 2021February 8, 2021

Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Show

News

First-line treatment with a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) failed to prolong survival and delay disease progression in patients with advanced non-small cell lung cancer (NSCLC) compared with ... Read more

February 1, 2021February 1, 2021

First Glioblastoma Patient Dosed in Phase 2 Trial Testing PVSRIPO Plus Keytruda

News

The first patient has been dosed in a Phase 2 trial assessing the safety and preliminary efficacy of PVSRIPO in combination with Keytruda (pembrolizumab) as a treatment for people with recurrent ... Read more

January 29, 2021January 29, 2021

EU Approves Keytruda as First-line Treatment for Certain Colorectal Cancers

News

The European Commission has approved Keytruda (pembrolizumab) as a first-line therapy for adults with metastatic colorectal cancer whose tumors have certain genetic features, the company announced. The genetic features, according to a press ... Read more

January 22, 2021January 22, 2021

FDA Agrees to Priority Review of Opdivo for Gastric, Esophageal Cancers

News

The U.S. Food and Drug Administration (FDA) has accepted for review — under priority status — two applications requesting the approval of Opdivo (nivolumab) for treating several types of gastric ... Read more

January 20, 2021January 20, 2021

Tecentriq-Avastin Combo Leads to ‘Longest Survival’ in Liver Cancer

News

First-line therapy with a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) significantly prolongs the survival of people with inoperable hepatocellular carcinoma (HCC) — the most common form of liver cancer ... Read more

January 18, 2021January 18, 2021

Less-frequent Dosing of Imfinzi Approved in Europe for Advanced Lung Cancer

News

A less-frequent, fixed dose regimen of Imfinzi (durvalumab) has been approved in the European Union and U.K. to treat adults with locally advanced, inoperable non-small cell lung cancer (NSCLC), announced ... Read more